香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。本 公 告 載 有 涉 及 風 險 及 不 明 確 因 素 的 前 瞻 性 陳 述。除 過 往 事 實 陳 述 以 外 的 所 有 陳 述 均 為 前 瞻 性 陳 述。該 等 陳 述 涉 及 已 知 及 未 知 的 風 險、不 明 確 及 其 他 因 素，當 中 部 分 並 非 本 公 司 所 能 控 制，且 可 導 致 實 際 業 績、表 現 或 成 果 與 該 等 前 瞻 性 陳 述 所 明 示 或 暗 示 者 存 在 重 大 差 異。 閣下不應依賴前瞻性陳述作為未來 事 件 的 預 測。本 公 司 概 不 承 擔 任 何 更 新 或 修 訂 任 何 前 瞻 性 陳 述 的 責 任，無 論 是 否 由 於 新 資 料、未 來 事 件 或 其 他 因 素 所 致。 （股 份 代 號：6978） 截 至2025年6月30日止六個月 中期業績公告 | ...

Core Insights - The recent government policies aim to support innovative drugs, including "first launch price protection" for CAR-T therapies, which will not be included in centralized procurement for the first five years post-launch [1] - Despite these policies, the payment challenges for CAR-T therapies remain significant, with prices ranging from 999,000 to 1,290,000 RMB, far exceeding the implicit thresholds of 300,000 RMB for basic medical insurance [1][2] - The focus for the 2025 negotiations will be on the long-term competitiveness of companies, assessing their ability to manage price pressures, cost control, and commercialization efficiency [2] Group 1: CAR-T Products and Pricing - Six CAR-T products will participate in commercial health insurance negotiations in September 2025, but basic medical insurance access is unlikely [3] - The current pricing for the listed CAR-T products is as follows: - Axicabtagene ciloleucel (Fosun Kite): 1,200,000 RMB - Relmacabtagene autoleucel (WuXi AppTec): 1,290,000 RMB - Nanjing Biomedicine's product: 999,000 RMB - Others range from 1,280,000 to 1,290,000 RMB [4] Group 2: Economic Evaluation and Price Pressure - Only three of the six CAR-T products have published cost-effectiveness analysis reports for the Chinese market, which will influence their negotiation positions [5] - The incremental cost-effectiveness ratios (ICER) for these products are as follows: - Axicabtagene ciloleucel: 463,000 RMB/QALY - Relmacabtagene autoleucel: 203,000 RMB/QALY - Other products show varying ICERs, indicating different levels of price pressure [6] Group 3: Competitive Strategies and Market Dynamics - The negotiation dynamics will depend on the companies' ability to demonstrate cost control and effective commercialization strategies [2][14] - Companies like WuXi AppTec and Legend Biotech have competitive advantages due to their existing ICERs being closer to the expected thresholds, while others may need to prove the reliability of unpublished data or offer price concessions [14] Group 4: Future Market Potential and Insurance Access - The potential for CAR-T therapies to enter the insurance market hinges on their ability to lower costs and expand patient access, particularly in the context of solid tumors [16][22] - The expected patient population for blood cancers is approximately 26,000 to 48,000 annually, while solid tumors could see a much larger patient base, enhancing the long-term viability of CAR-T therapies [20][22] Group 5: Key Observations for Investors - The completeness of health economic data will determine the negotiation eligibility for insurance access, while the feasibility of price reductions and commercialization efficiency will influence the speed of market entry [14][15] - The ability to expand hospital coverage and partnerships with health insurance will be critical for companies to achieve rapid market penetration and revenue growth [15]

格隆汇8月8日丨永泰生物-B(06978.HK)公告，公司计划于2025年8月20日(星期三)举行董事会会议，藉 以(其中包括)考虑及批准公司及其附属公司截至2025年6月30日止6个月中期业绩及其发布。 ...

永泰生物製藥有限公司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司 計劃於2025年8月20日（星 期 三）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考慮及批准本 公司及其附屬公司截至2025年6月30日 止 六 個 月 之 中 期 業 績 及 其 發 佈。 承董事會命 永泰生物製藥有限公司 香 港 交 易 及 結 算 所 有 限 公 司、香 港 聯 合 交 易 所 有 限 公 司 及 香 港 中 央 結 算 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Immunotech Biopharm Ltd 永泰生物製藥有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 董事會會議日期 主席兼執行董事 譚 錚 香 港，2025年8月8日 於 本 公 告 日 期，董 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 永泰生物製藥有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06978 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | FF301 II. ...

Core Insights - As of March 2025, China's foreign financial assets are projected to reach 106,978 billion USD, with foreign liabilities at 70,854 billion USD, resulting in a net foreign asset of 36,124 billion USD [1] Summary by Category Foreign Financial Assets - Direct investment assets amount to 32,765 billion USD - Securities investment assets total 15,818 billion USD - Financial derivative assets are valued at 211 billion USD - Other investment assets stand at 22,845 billion USD - Reserve assets are recorded at 35,339 billion USD [1] Foreign Liabilities - Total foreign liabilities are 70,854 billion USD [1] Net Foreign Assets - The net foreign assets are calculated to be 36,124 billion USD [1] SDR Valuation - In terms of Special Drawing Rights (SDR), foreign financial assets are valued at 80,513 billion SDR, while foreign liabilities are at 53,326 billion SDR, leading to a net foreign asset of 27,188 billion SDR [1]

Clinical Trials and Product Development - The company has completed the enrollment of 430 target subjects for the Phase II clinical trial of its core candidate product EAL®, with conditional NDA acceptance by the National Medical Products Administration[9]. - The company plans to submit for commercialization of EAL® in the Chinese market following statistically significant clinical trial results[7]. - The company has completed the enrollment of six target patients for the Phase I clinical trial of 6B11-OCIK injection, with preliminary analysis and mid-term results ongoing[10]. - The CAR-T-19 injection has received breakthrough therapy designation from the drug review center for treating relapsed/refractory B-ALL patients aged 25 and under, expediting its clinical development[13]. - The company has completed the enrollment of 47 target patients for the Phase II clinical trial of CAR-T-19 injection[14]. - The company has completed the enrollment of 12 target patients for the Phase I clinical trial of Dinolansai injection as of the report date[16]. - The company has received IND approval for the Phase I clinical trial of aT19 injection in February 2024[17]. - The group has obtained clinical implicit approval from the National Medical Products Administration for Dinolansai injection, aimed at treating patients with relapsed refractory diffuse large B-cell lymphoma[33]. - The group has completed the enrollment of 12 target patients in the Phase I clinical trial for Dinolansai injection[34]. - The company aims to address the challenges of CAR-T cell therapy's persistence and efficacy with the development of Dinolansai and aT19 injections[17]. - The company is progressing with the clinical development of multiple TCR-T cell products targeting renal clear cell carcinoma and viral infections[18]. Financial Performance - Other income increased from approximately RMB 10.5 million for the year ending December 31, 2023, to approximately RMB 33.8 million for the year ending December 31, 2024, representing a growth of about 220.4%[21]. - The net loss decreased from approximately RMB 106.5 million for the year ending December 31, 2023, to approximately RMB 11.8 million for the year ending December 31, 2024, a reduction of about 88.9%[21]. - R&D expenses decreased from approximately RMB 177.3 million for the year ending December 31, 2023, to approximately RMB 154.2 million for the year ending December 31, 2024, a decrease of about 13.0%[21]. - The total loss and comprehensive expenses decreased from approximately RMB 335.5 million for the year ending December 31, 2023, to approximately RMB 187.3 million for the year ending December 31, 2024, a reduction of about 44.2%[22]. - The net loss decreased by approximately 44.4% from RMB 335.5 million in 2023 to RMB 186.4 million in 2024, reflecting improvements in operational efficiency[60]. - Research and development expenses decreased by approximately 13.0% from RMB 177.3 million in 2023 to RMB 154.2 million in 2024, mainly due to increased material costs offset by reduced contracted costs and employee expenses[57]. - Administrative expenses decreased by approximately 16.4% from RMB 53.2 million in 2023 to RMB 44.5 million in 2024, attributed to reductions in employee costs and professional fees[56]. - Cash and cash equivalents decreased from approximately RMB 52.2 million in 2023 to RMB 47.0 million in 2024, primarily due to cash consumption for R&D[63]. - The company reported a financial cost reduction of approximately 12.0% from RMB 8.5 million in 2023 to RMB 7.5 million in 2024, mainly due to decreased interest expenses on lease liabilities[58]. Research and Development Initiatives - The company has established a proprietary technology platform for the production of EAL® cells, enhancing its R&D capabilities[7]. - The company’s product pipeline includes non-gene modified and gene modified products, with a focus on multi-target and single-target cell immunotherapy products[7]. - The company has been focusing on T-cell immunotherapy research and commercialization for nearly 18 years, demonstrating a strong commitment to cancer treatment[7]. - The company aims to advance its clinical research and commercialization processes through a well-structured R&D organization[7]. - The company aims to develop a TCR gene database targeting new tumor antigens for personalized cancer immunotherapy[47]. - The company has established a virus vector production system that meets GMP standards, enabling large-scale production of viral vectors for CAR-T cell therapy[48]. Strategic Partnerships and Market Expansion - The company plans to expand strategic partnerships and explore acquisition opportunities to enhance the sales and development of existing and new products[49]. - The company aims to expand its market presence and enhance its product offerings through strategic partnerships and acquisitions[96]. - The management team is committed to exploring new strategies for market expansion and product development[88]. - The company is focused on advancing its research and development initiatives, particularly in biotechnology and pharmaceuticals[93][96]. Corporate Governance and Management - The management team includes experienced professionals with over 20 years in the pharmaceutical industry, contributing to strategic planning and operational oversight[86][87]. - The independent non-executive directors provide independent opinions and judgments to the board, ensuring governance and oversight[93][94]. - The company is committed to maintaining high standards of corporate governance through the involvement of experienced independent directors[93][94]. - The management team has a strong educational background, with degrees from prestigious institutions, contributing to informed decision-making[90][91][96]. Employee and Operational Management - The company is focused on employee training to enhance technical and product knowledge, offering various training programs tailored to different positions[81]. - The company provides social insurance and housing provident fund contributions for all employees in China[82]. - The total employee compensation for the year was approximately RMB 70.1 million, a decrease from RMB 77.0 million in 2023[77]. - The company has 154 employees as of December 31, 2024, with the largest functional group being production, purification, equipment, and safety, comprising 56 employees[78]. Risks and Challenges - The company has incurred a net loss during the reporting period and has not generated any revenue from self-sales of its research products, with no guarantee of future profitability[105]. - The company anticipates needing additional financing to support its operations, including research and commercialization efforts, due to negative operating cash flow during the reporting period[105]. - The company faces significant risks related to the inability to identify or develop new products, which could lead to investor losses[105]. - The company may face challenges in obtaining regulatory approvals for its research products, which are currently in preclinical or clinical development stages[105]. - The company is subject to strict regulatory oversight in drug development and commercialization, which may impact its operational timelines[108]. - The company faces risks related to its operations in China, including potential fines for non-compliance with employee welfare regulations and challenges in managing growth[110]. Shareholder and Financial Structure - The company issued convertible bonds totaling RMB 300 million on February 20, 2023, with an initial conversion price of HKD 4.81 per share[68]. - As of December 31, 2024, the company utilized approximately RMB 256.6 million of the proceeds from the convertible bonds, with RMB 102.3 million allocated for EAL® clinical trials and RMB 197.7 million for the construction of a new R&D and production center[72]. - The company's capital structure as of December 31, 2024, was 102.9% debt and -2.9% equity, compared to 79.8% debt and 20.2% equity as of December 31, 2023[67]. - The company has a distributable reserve of RMB 1,402,498,000 as of December 31, 2024, unchanged from 2023[172]. - The company has adopted a stable and conservative financing policy to maintain optimal financial conditions and minimize financial risks[124]. Legal and Compliance Matters - There are ongoing lawsuits from two suppliers regarding overdue payments, but the board believes the impact on the financial statements is not significant[174]. - The company has established contractual arrangements to maintain effective control over its operations in China, particularly in the field of immunotherapy[179]. - The exclusive business cooperation agreement grants the company exclusive and proprietary rights to all intellectual property developed by its subsidiary[183]. - The share pledge agreement was established on September 10, 2018, to secure the obligations of the registered shareholders towards Beijing Yongtai[184].

Financial Performance - Other income increased from approximately RMB 10.5 million for the year ended December 31, 2023, to approximately RMB 33.8 million for the year ended December 31, 2024, representing a growth of about 220.4%[3]. - Net loss from other gains and losses decreased from approximately RMB 106.5 million for the year ended December 31, 2023, to approximately RMB 11.8 million for the year ended December 31, 2024, a reduction of about 88.9%[3]. - Loss before tax decreased from approximately RMB 335.5 million for the year ended December 31, 2023, to approximately RMB 186.4 million for the year ended December 31, 2024, a decrease of about 44.4%[3]. - Total loss and comprehensive expenses decreased from approximately RMB 335.5 million for the year ended December 31, 2023, to approximately RMB 187.3 million for the year ended December 31, 2024, a reduction of about 44.2%[4]. - The total loss for the year ended December 31, 2024, was RMB 187.3 million, compared to RMB 335.5 million for the year ended December 31, 2023[38]. - The company reported a net loss of RMB 187,343,000 for the year ending December 31, 2024, compared to a net loss of RMB 335,479,000 in the previous year, indicating an improvement[97]. - The group reported a net loss attributable to shareholders of RMB 186,912,000 for the year ended December 31, 2024, compared to a loss of RMB 334,819,000 in 2023, indicating an improvement of approximately 44%[129]. Research and Development - R&D expenses decreased from approximately RMB 177.3 million for the year ended December 31, 2023, to approximately RMB 154.2 million for the year ended December 31, 2024, a decline of about 13.0%[3]. - The company has completed the enrollment of 430 target patients for the Phase II clinical trial of EAL®, with the application for conditional approval submitted to the NMPA[5]. - The company has completed the enrollment of six target patients for the Phase I clinical trial of 6B11-OCIK injection and is conducting preliminary analysis of the trial results[6]. - CAR-T-19 injection has received breakthrough therapy designation for the treatment of patients aged 25 and under with relapsed/refractory B-ALL, expediting its clinical development[8]. - The company has completed the enrollment of 12 target patients for the Phase I clinical trial of Dinolones injection[9]. - The company has multiple TCR-T cell products in preclinical research targeting indications such as renal cell carcinoma and viral infections like CMV and EBV[12]. - The YT007 injection for treating advanced renal cell carcinoma has completed preclinical research[13]. - The core candidate product EAL® has received acceptance for its NDA from the NMPA, with a focus on preventing postoperative recurrence of liver cancer[14][19]. - The company has established a technical platform necessary for the development of cell immunotherapy products[15]. - The company has established a virus vector production system that meets GMP standards, enabling large-scale production of viral vectors for CAR-T cell enterprises[36]. - The company aims to continue investing in CAR-T and TCR-T cell product pipelines, targeting CMV infections in patients post-transplant[34]. - The company is focused on the research and development of new drugs, particularly in the field of immune cell therapy[151]. Financial Management - Cash and bank balances decreased from approximately RMB 52.2 million as of December 31, 2023, to RMB 47.0 million as of December 31, 2024, primarily due to cash used in R&D[52]. - The liquidity ratios showed a decline, with the current ratio decreasing from 0.40 in 2023 to 0.20 in 2024, and the quick ratio decreasing from 0.39 to 0.19 during the same period[63]. - The company has no interest-bearing debt as of December 31, 2024, making the debt-to-equity ratio not applicable[67]. - The company aims to enhance its operational capital and financial condition through the issuance of convertible bonds, despite potential dilution effects on existing shareholders[58]. - The company has significant uncertainties regarding its ability to continue as a going concern due to ongoing losses and cash flow issues[94]. - The group has significant uncertainty regarding its ability to continue as a going concern, dependent on the successful implementation of its plans and measures[113]. - The company has received recognition as a "High-tech Enterprise," allowing it to benefit from a reduced corporate income tax rate of 15%[122]. Employee and Operational Costs - Employee compensation for the year totaled approximately RMB 70.1 million, down from RMB 77.0 million in 2023[75]. - Total employee costs for 2024 are RMB 70,053,000, down from RMB 77,034,000 in 2023, reflecting a decrease of approximately 9.5%[127]. - The company employed a total of 154 employees as of December 31, 2024[76]. - The quality department had 39 employees as of December 31, 2024, and reports directly to the CEO[32]. Capital and Investment - The company issued convertible bonds totaling RMB 300 million on February 20, 2023, with an initial conversion price of HKD 4.81 per share[57]. - The company raised a total of RMB 300 million through the issuance of convertible bonds, with RMB 102.3 million allocated for EAL® clinical trials and RMB 197.7 million for the construction of a new R&D and production center[60]. - As of December 31, 2024, the company utilized approximately RMB 240.2 million of the funds raised from the convertible bonds, with RMB 102.3 million fully used for EAL® clinical trials and RMB 154.3 million used for the new R&D center[61]. - The company plans to invest approximately RMB 1.2 billion in the Beijing production center, expected to produce over 200,000 batches of cell drugs annually[30]. - A project in the East China region is expected to have a total investment of around RMB 1 billion, with the first phase of the EAL® R&D and production center to be completed within 48 months after obtaining land ownership[30]. Compliance and Governance - The audit committee has confirmed compliance with applicable accounting principles and standards for the financial year ending December 31, 2024[90]. - Deloitte has agreed that the preliminary announcement figures align with the audited consolidated financial statements to be approved on March 31, 2025[91]. - The company has adopted the standards set forth in the listing rules to regulate securities trading by directors and related employees[86]. - The company is focused on ensuring compliance with the listing rules of the Hong Kong Stock Exchange[151]. Future Outlook - The company plans to accelerate the commercialization of EAL® and is focusing on government affairs, hospital admissions, market, medical, and sales-related work[33]. - The company is actively seeking equity financing and applying for applicable government subsidies[112]. - The company is exploring market expansion opportunities in the biopharmaceutical sector[152]. - The company plans to fully utilize the net proceeds by 2025[72].

Financial Performance - Total revenue for the six months ended June 30, 2024, was RMB 6,526,000, representing a 17.9% increase from RMB 5,533,000 in the same period of 2023[16]. - The pre-tax loss for the period was RMB 92,556,000, a decrease of 22.0% from RMB 118,602,000 in the previous year[16]. - Basic and diluted loss per share was RMB 0.18, improved from RMB 0.23 in the same period last year[16]. - Other income increased by approximately 17.9% to RMB 6.5 million for the six months ended June 30, 2024, compared to RMB 5.5 million for the same period in 2023, primarily due to increased government subsidies[32]. - The group recorded a net other income of approximately RMB 19.8 million for the six months ended June 30, 2024, compared to a net loss of approximately RMB 20.3 million for the same period in 2023, mainly due to fair value gains on other financial liabilities[33]. - Administrative expenses decreased by approximately 7.9% to RMB 23.0 million for the six months ended June 30, 2024, from RMB 25.0 million for the same period in 2023, mainly due to reduced travel and other expenses[34]. - The group's loss before tax decreased by approximately 22.0% to RMB 92.6 million for the six months ended June 30, 2024, compared to RMB 118.6 million for the same period in 2023[37]. - The company reported a total comprehensive loss for the period attributable to owners of the company of RMB 92,515,000, compared to RMB 118,114,000 in the previous year, reflecting a decrease of 21.7%[88]. - The company reported a loss attributable to owners of RMB 92,515,000 for the six months ended June 30, 2024, compared to a loss of RMB 118,114,000 in the same period of 2023[109]. Research and Development - Research and development expenses increased by 22.6% to RMB 91,118,000 compared to RMB 74,315,000 in the prior year[16]. - The company is focused on the commercialization of its core product EAL® for the prevention of postoperative recurrence of liver cancer[17]. - The product pipeline includes non-gene modified and gene modified cell immunotherapy products, with ongoing research on 6B11, CAR-T cell series, and TCR-T cell series[17]. - EAL® is undergoing a Phase II clinical trial for preventing postoperative recurrence of liver cancer, with interim results expected to support a New Drug Application (NDA) submission in the second half of 2024[19]. - The company has completed enrollment of 430 target patients for the Phase II clinical trial of EAL® and anticipates submitting the NDA to the National Medical Products Administration in the second half of 2024, with a product launch expected in 2025[20]. - The 6B11-OCIK injection for ovarian cancer has completed enrollment of six target patients in its Phase I clinical trial, with preliminary analysis and mid-term results ongoing[21]. - CAR-T-19 injection, targeting B-ALL in patients aged 25 and under, has completed enrollment of 25 target patients for its Phase II clinical trial, with preliminary results expected in the first half of 2026[21]. - The company has completed enrollment of eight target patients for the Phase I clinical trial of the dinutuximab injection, with completion expected by the end of 2024 and preliminary results in the first half of 2025[22]. - The company is developing TCR-T-CMV, the first product targeting CMV-related malignancies, with plans to enter clinical trials in 2025[29]. - The company is focused on enhancing the efficacy and durability of CAR-T cell therapies through innovative product development[23]. - The company is actively pursuing regulatory approvals and clinical trials to bring its innovative therapies to market[20]. Financial Position - Non-current assets as of June 30, 2024, were RMB 538,889,000, down 14.8% from RMB 632,390,000 at the end of 2023[16]. - Current assets decreased by 15.5% to RMB 180,830,000 from RMB 213,894,000 at the end of 2023[16]. - Current liabilities were RMB 478,206,000, a reduction of 9.8% from RMB 530,275,000 at the end of 2023[16]. - The company's capital structure as of June 30, 2024, consisted of 89.1% debt and 10.9% equity, compared to 62.6% debt and 37.4% equity as of June 30, 2023[42]. - The company has no outstanding mortgages, pledges, or significant contingent liabilities as of June 30, 2024[41]. - The company reported a bank balance and cash increase from approximately RMB 52.2 million to approximately RMB 79.6 million as of June 30, 2024, primarily due to the sale of deposit notes[40]. - The company has accumulated losses of RMB 1,712,662,000 as of June 30, 2024, which has expanded from the previous reported losses[93]. - The company plans to implement measures to improve liquidity, including financial support from a major shareholder for at least 15 months starting December 31, 2023[93]. - The company is actively applying for applicable government subsidies to enhance its financial position[94]. Investments and Capital Expenditures - The company plans to invest approximately RMB 1.2 billion in the Beijing production center, which is expected to produce over 200,000 batches of cell drugs annually, covering the northern and northeastern markets of China[26]. - A production center in the East China region is projected to have a total investment of around RMB 1 billion, with the first phase of construction expected to be completed within 60 months after obtaining land rights[27]. - The company plans to utilize approximately RMB 197.7 million for the construction costs of a new R&D and production center, with expected utilization by the end of 2025[44]. - The company has capital commitments for machinery, leased land, and construction projects as of June 30, 2024, amounting to RMB 561,406,000, a decrease from RMB 573,993,000 as of December 31, 2023[126]. Shareholder Information - The company has issued convertible bonds totaling RMB 300 million in February 2023, with an annual interest rate of 6%[43]. - Approximately RMB 102.3 million of the funds from the convertible bonds will be used for EAL® clinical trials, with expected utilization by the first half of 2025[44]. - The company has a total of 5,000,000 shares held by Mr. Tan Zheng, representing 0.97% of the company's equity[55]. - Major shareholder China Resources Limited holds 217,054,121 shares, representing 42.18% of the company's equity[59]. - The company has a total of 38,400,000 shares held by Tan Zheng Ltd, representing 7.46% of the company's equity[60]. - The company has issued a total of 514,584,000 shares as of the mid-term report date[61]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance codes throughout the six months ending June 30, 2024, ensuring shareholder rights and enhancing corporate value[68]. - The audit committee, consisting of three members, has reviewed the unaudited interim results for the six months ending June 30, 2024, confirming compliance with applicable accounting principles and standards[71]. - The company emphasizes the importance of regulatory compliance in its operations, adhering to the Securities and Futures Ordinance of Hong Kong[137]. Future Outlook - The company has a future outlook focused on market expansion and new product development, although specific figures were not disclosed in the provided content[58]. - The company is exploring strategic partnerships and potential acquisitions to enhance its market position[58]. - The company is committed to ongoing research and development in new technologies to drive future growth[58]. - The company aims to expand its market presence through strategic collaborations and investments in innovative technologies[138].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。本 公 告 載 有 涉 及 風 險 及 不 明 確 因 素 的 前 瞻 性 陳 述。除 過 往 事 實 陳 述 以 外 的 所 有 陳 述 均 為 前 瞻 性 陳 述。該 等 陳 述 涉 及 已 知 及 未 知 的 風 險、不 明 確 及 其 他 因 素，當 中 部 分 並 非 本 公 司 所 能 控 制，且 可 導 致 實 際 業 績、表 現 或 成 果 與 該 等 前 瞻 性 陳 述 所 明 示 或 暗 示 者 存 在 重 大 差 異。 閣下不應依賴前瞻性陳述作為未來 事 件 的 預 測。本 公 司 概 不 承 擔 任 何 更 新 或 修 訂 任 何 前 瞻 性 陳 述 的 責 任，無 論 是 否 由 於 新 資 料、未 來 事 件 或 其 他 因 素 所 致。 Immunotech Biopharm Ltd 永泰生物製藥有限公司 （於 開 曼 ...